AstraZeneca Inks Back-Loaded $1.15B Deal For US Drugmaker
AstraZeneca PLC on Monday announced a $1.15 billion deal for venture-backed respiratory-drug maker Pearl Therapeutics as it continues to use acquisitions to replenish expiring patents and a disappointing research pipeline....To view the full article, register now.
Already a subscriber? Click here to view full article